Clinical Investigation of the Multifocal IOL POD F GF in Cataracteous Eyes

Cataract Clinical Trial

Official title:

Clinical Investigation of the Multifocal Intraocular Lens (IOL) POD F GF in Cataracteous Eyes

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04699266
• Other study ID #: PHY2002
• Status: Completed
• Phase: N/A
• Start date: November 1, 2020
• Est. completion date: August 30, 2021

Study information

• Verified date: July 2023
• Source: Beaver-Visitec International, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

To evaluate effectiveness and safety of the POD F GF Intraocular Lens (IOL) when implanted to replace the natural lens following cataract removal

Description:

Since the investigational lens, like conventional IOLs, is a posterior chamber lens which is widely implanted following cataract extraction, phacoemulsification is adopted. To assess the binocular vision, the investigational lens will be bilaterally implanted. Considering the safety of the study subjects, the time of implant to the remaining eye (2nd eye) will be decided based on the results of the 1st implant.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 23
• Est. completion date: August 30, 2021
• Est. primary completion date: August 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Adults, 20 years of age or older at the time of informed consent, of either gender, diagnosed with bilateral cataracts;

2. Able to comprehend and sign a statement of informed consent;

3. Willing and able to complete all required postoperative visits;

4. Calculated lens power within the available range;

5. Planned cataract removal by phacoemulsification;

6. Potential postoperative BCDVA of 0.5 decimal or better in both eyes;

7. Subject with preoperative astigmatism < 1.0 D

8. Clear intraocular media other than cataract in both eyes;

9. The subject must be able to undergo second eye surgery within 30 days of the first eye surgery.

[Justification for the inclusion criteria]

1. and 5: Cataract extraction is the indication of the clinical study.

2. and 3: One of GCP requirements 4: Essential condition for implant of the investigational lens. 6, 7, 8 and 9: Conditions to minimize the potential non-IOL factors which may affect the visual acuity data

Exclusion Criteria:

[Exclusion Criteria Prior to Surgery] The patient who meets any criteria specified in the following 1) through 22).

1. Irregular corneal aberration that affects postoperative visual function as demonstrated by corneal topography;

2. Inflammation or edema (swelling) of the cornea affecting post-operative visual acuity;

3. Subjects with diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future acuity losses to a level worse than 0.5 decimal for BCDVA;

4. Subjects who may be expected to require ocular surgery (other than blepharo-surgery, laser surgery of fundus and YAG capsulotomy) during the study;

5. Previous refractive surgery;

6. Amblyopia;

7. Clinically severe corneal dystrophy (eg., epithelial, stromal, or endothelial dystrophy), keratitis, keratoconjunctivitis, keratouveitis, keratopathy, or kerectasia;

8. Diabetic retinopathy;

9. Extremely shallow anterior chamber, not due to swollen cataract;

10. Microphthalmos;

11. Current or previous retinal detachment;

12. Previous corneal transplant;

13. Recurrent severe anterior or posterior segment inflammation of unknown etiology;

14. Rubella or traumatic cataract;

15. Iris neovascularization;

16. Glaucoma or ocular hypertension;

17. Aniridia;

18. Optic nerve atrophy;

19. Planned clear lensectomy (no lens opacity)

20. Pregnancy, lactating or possible pregnant;

21. Participation in any clinical study (drug or device) within 3 months prior to participating this study, planned participation another clinical study during this study, or currently participating in another study.

22. Disqualified by the investigator or the sub-investigator because of physical or ophthalmic diseases.

[Exclusion Criteria During Surgery] The patient who meets any criteria specified in the following 1) through 7).

1. Mechanical or surgical manipulation required to enlarge the pupil;

2. Excessive iris mobility;

3. Significant vitreous loss;

4. Significant anterior chamber hyphema;

5. Uncontrollable intraocular pressure;

6. Zonular or capsular rupture or tear;

7. IOL could not be fixed in the lens capsule;

Related Conditions & MeSH terms

• Cataract
• Lens Opacities
• Presbyopia

Intervention

Device:
• Assigned Intervention (POD F GF)
The investigational lens (POD F GF )will be implanted to both eyes in subjects with bilateral cataract. Registration of patients and the implantation of the investigational lens (POD F GF) will be conducted in consideration of securing 44 eyes in 22 subjects as the analysis subjects

Locations

Country	Name	City	State
Japan	Miyata Eye Hospital	Miyata

Sponsors (1)

Lead Sponsor	Collaborator
Beaver-Visitec International, Inc.

Country where clinical trial is conducted

Japan, 

References & Publications (1)

Mori Y, Miyata K, Suzuki H, Noguchi S, Ichikawa K, Maeda N. Clinical Performance of a Hydrophobic Acrylic Diffractive Trifocal Intraocular Lens in a Japanese Population. Ophthalmol Ther. 2023 Apr;12(2):867-878. doi: 10.1007/s40123-022-00634-4. Epub 2022 D — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Binocular Best corrected distance visual acuity (5 m)	CDVA measured with ETDRS charts placed in 5m distance with best aided corrective glasses according to ISO 11979-7:2014.	Postoperative Day 120-180 (4-6 months)
Primary	Binocular Distance corrected near visual acuity (40 cm)	DCIVA measured with ETDRS charts placed in 40cm distance with corrective glasses for far distance according to ISO 11979-7:2014.	Postoperative Day 120-180 (4-6 months)
Primary	Binocular Distance corrected intermediate visual acuity (80 cm)	DCIVA measured with ETDRS charts placed in 80cm distance with corrective glasses for far distance according to ISO 11979-7:2014.	Postoperative Day 120-180 (4-6 months)
Secondary	Binocular photopic best corrected distance visual acuity (5 m)	DCIVA outcomes at 5m distance	Postoperative Day 120-180
Secondary	Monocular and binocular photopic uncorrected distance visual acuity (5 m)	UDVA outcomes at n 5m distance	Postoperative Day 120-180
Secondary	Monocular and binocular photopic uncorrected intermediate visual acuity and binocular distance corrected intermediate visual acuity (80 cm)	DCIVA outcomes at 80cm distance	Postoperative Day 120-180
Secondary	Monocular and binocular photopic uncorrected near visual acuity and binocular distance corrected visual acuity (40cm)	DCNVA outcomes at 40cm distance	Postoperative Day 120-180
Secondary	Binocular photopic defocus curves	To assess the visual acuity for different distances, defocus curves under photopic light conditions are measured. This test is performed with best distance corrected refraction and spherical additions ranging from -5.0 D to +1.5 D.	Postoperative Day 120-180
Secondary	Contrast Sensitivity under photopic light conditions	Contrast Sensitivity outcomes under photopic light conditions	Postoperative Day 120-180
Secondary	Contrast Sensitivity under mesopic light conditions	Contrast Sensitivity outcomes under photopic light conditions	Postoperative Day 120-180
Secondary	Quality of Vison: VFQ-11 Questionnaire	Outcomes measures of a questionnaire to address the general patient satisfaction and possible side effects of the treatment. For this study, the validated and verified Visual Functioning Questionnaire - 25 (VFQ-25) will be used. The maximum score for each questionaire is 100.	Postoperative Day 120-180

External Links

•   Official study publication of Clinical results